U
CEN Biotech, Inc.
CENBF
$0.0001
$0.000.00%
D
Sell
10/6/2023Upgraded
CEN Biotech, Inc. (CENBF) was upgraded to D- from E+ on 10/6/2023 due to a substantial increase in the valuation index and volatility index.
CEN Biotech, Inc. (CENBF) was upgraded to D- from E+ on 10/6/2023 due to a substantial increase in the valuation index and volatility index.
E
Sell
9/14/2023Downgrade
CEN Biotech, Inc. (CENBF) was downgraded to E+ from D- on 9/14/2023 due to a decline in the volatility index.
CEN Biotech, Inc. (CENBF) was downgraded to E+ from D- on 9/14/2023 due to a decline in the volatility index.
D
Sell
8/29/2023Upgraded
CEN Biotech, Inc. (CENBF) was upgraded to D- from E+ on 8/29/2023 due to an increase in the volatility index.
CEN Biotech, Inc. (CENBF) was upgraded to D- from E+ on 8/29/2023 due to an increase in the volatility index.
E
Sell
8/14/2023Downgrade
CEN Biotech, Inc. (CENBF) was downgraded to E+ from D- on 8/14/2023 due to a decline in the volatility index and total return index.
CEN Biotech, Inc. (CENBF) was downgraded to E+ from D- on 8/14/2023 due to a decline in the volatility index and total return index.
D
Sell
7/18/2023Upgraded
CEN Biotech, Inc. (CENBF) was upgraded to D- from E+ on 7/18/2023 due to an increase in the volatility index.
CEN Biotech, Inc. (CENBF) was upgraded to D- from E+ on 7/18/2023 due to an increase in the volatility index.
E
Sell
6/30/2023Downgrade
CEN Biotech, Inc. (CENBF) was downgraded to E+ from D- on 6/30/2023 due to a decline in the volatility index.
CEN Biotech, Inc. (CENBF) was downgraded to E+ from D- on 6/30/2023 due to a decline in the volatility index.
D
Sell
6/12/2023Upgraded
CEN Biotech, Inc. (CENBF) was upgraded to D- from E+ on 6/12/2023 due to an increase in the volatility index and total return index.
CEN Biotech, Inc. (CENBF) was upgraded to D- from E+ on 6/12/2023 due to an increase in the volatility index and total return index.
E
Sell
5/24/2023Downgrade
CEN Biotech, Inc. (CENBF) was downgraded to E+ from D- on 5/24/2023 due to a decline in the volatility index.
CEN Biotech, Inc. (CENBF) was downgraded to E+ from D- on 5/24/2023 due to a decline in the volatility index.
D
Sell
5/8/2023Upgraded
CEN Biotech, Inc. (CENBF) was upgraded to D- from E+ on 5/8/2023 due to an increase in the volatility index and total return index.
CEN Biotech, Inc. (CENBF) was upgraded to D- from E+ on 5/8/2023 due to an increase in the volatility index and total return index.
E
Sell
4/21/2023Downgrade
CEN Biotech, Inc. (CENBF) was downgraded to E+ from D- on 4/21/2023 due to a decline in the volatility index and valuation index.
CEN Biotech, Inc. (CENBF) was downgraded to E+ from D- on 4/21/2023 due to a decline in the volatility index and valuation index.
D
Sell
4/5/2023Upgraded
CEN Biotech, Inc. (CENBF) was upgraded to D- from E+ on 4/5/2023 due to an increase in the volatility index and total return index.
CEN Biotech, Inc. (CENBF) was upgraded to D- from E+ on 4/5/2023 due to an increase in the volatility index and total return index.
E
Sell
3/21/2023Downgrade
CEN Biotech, Inc. (CENBF) was downgraded to E+ from D- on 3/21/2023 due to a decline in the volatility index and total return index.
CEN Biotech, Inc. (CENBF) was downgraded to E+ from D- on 3/21/2023 due to a decline in the volatility index and total return index.
D
Sell
3/3/2023Upgraded
CEN Biotech, Inc. (CENBF) was upgraded to D- from E+ on 3/3/2023 due to an increase in the volatility index and total return index.
CEN Biotech, Inc. (CENBF) was upgraded to D- from E+ on 3/3/2023 due to an increase in the volatility index and total return index.
E
Sell
2/15/2023Downgrade
CEN Biotech, Inc. (CENBF) was downgraded to E+ from D- on 2/15/2023 due to a decline in the volatility index and total return index.
CEN Biotech, Inc. (CENBF) was downgraded to E+ from D- on 2/15/2023 due to a decline in the volatility index and total return index.
D
Sell
1/26/2023Upgraded
CEN Biotech, Inc. (CENBF) was upgraded to D- from E+ on 1/26/2023 due to an increase in the volatility index and total return index.
CEN Biotech, Inc. (CENBF) was upgraded to D- from E+ on 1/26/2023 due to an increase in the volatility index and total return index.
E
Sell
1/10/2023Downgrade
CEN Biotech, Inc. (CENBF) was downgraded to E+ from D- on 1/10/2023 due to a decline in the volatility index and total return index.
CEN Biotech, Inc. (CENBF) was downgraded to E+ from D- on 1/10/2023 due to a decline in the volatility index and total return index.
D
Sell
12/12/2022Upgraded
CEN Biotech, Inc. (CENBF) was upgraded to D- from E+ on 12/12/2022 due to an increase in the volatility index.
CEN Biotech, Inc. (CENBF) was upgraded to D- from E+ on 12/12/2022 due to an increase in the volatility index.
E
Sell
11/25/2022Downgrade
CEN Biotech, Inc. (CENBF) was downgraded to E+ from D- on 11/25/2022 due to a large decline in the growth index, efficiency index and volatility index. Total revenue declined 74.95% from $542.5 to $135.9, EBIT declined 62.13% from -$300 to -$486.4, and net income declined 14.9% from -$348.3 to -$400.2.
CEN Biotech, Inc. (CENBF) was downgraded to E+ from D- on 11/25/2022 due to a large decline in the growth index, efficiency index and volatility index. Total revenue declined 74.95% from $542.5 to $135.9, EBIT declined 62.13% from -$300 to -$486.4, and net income declined 14.9% from -$348.3 to -$400.2.
D
Sell
8/25/2022Upgraded
CEN Biotech, Inc. (CENBF) was upgraded to D- from E+ on 8/25/2022 due to a large increase in the growth index, volatility index and efficiency index. Total revenue increased 59.42% from $340.3 to $542.5, earnings per share increased from -$0.0061 to -$0.0057, and total capital increased 2.72% from $3.63M to $3.73M.
CEN Biotech, Inc. (CENBF) was upgraded to D- from E+ on 8/25/2022 due to a large increase in the growth index, volatility index and efficiency index. Total revenue increased 59.42% from $340.3 to $542.5, earnings per share increased from -$0.0061 to -$0.0057, and total capital increased 2.72% from $3.63M to $3.73M.
E
Sell
4/18/2022Downgrade
CEN Biotech, Inc. (CENBF) was downgraded to E+ from D- on 4/18/2022 due to a major decline in the efficiency index, growth index and total return index. Operating cash flow declined 471.5% from $21.4 to -$79.5, net income declined 187.73% from -$718.9 to -$2.07M, and earnings per share declined from -$0.0152 to -$0.0419.
CEN Biotech, Inc. (CENBF) was downgraded to E+ from D- on 4/18/2022 due to a major decline in the efficiency index, growth index and total return index. Operating cash flow declined 471.5% from $21.4 to -$79.5, net income declined 187.73% from -$718.9 to -$2.07M, and earnings per share declined from -$0.0152 to -$0.0419.
D
Sell
11/22/2021Upgraded
CEN Biotech, Inc. (CENBF) was upgraded to D- from E+ on 11/22/2021 due to a substantial increase in the growth index, efficiency index and solvency index. The quick ratio increased from 0 to 0.03, operating cash flow increased 109.89% from -$216.3 to $21.4, and total capital increased 101.72% from $1.86M to $3.74M.
CEN Biotech, Inc. (CENBF) was upgraded to D- from E+ on 11/22/2021 due to a substantial increase in the growth index, efficiency index and solvency index. The quick ratio increased from 0 to 0.03, operating cash flow increased 109.89% from -$216.3 to $21.4, and total capital increased 101.72% from $1.86M to $3.74M.
E
Sell
8/13/2021Downgrade
CEN Biotech, Inc. (CENBF) was downgraded to E+ from D- on 8/13/2021 due to a significant decline in the valuation index, growth index and total return index. EBIT declined 4,616.82% from -$344.8 to -$16.26M, earnings per share declined from -$0.0226 to -$0.3817, and operating cash flow declined 254.01% from -$61.1 to -$216.3.
CEN Biotech, Inc. (CENBF) was downgraded to E+ from D- on 8/13/2021 due to a significant decline in the valuation index, growth index and total return index. EBIT declined 4,616.82% from -$344.8 to -$16.26M, earnings per share declined from -$0.0226 to -$0.3817, and operating cash flow declined 254.01% from -$61.1 to -$216.3.
D
Sell
5/17/2021None
CEN Biotech, Inc. (CENBF) was downgraded to D- from U on 05/17/2021.
CEN Biotech, Inc. (CENBF) was downgraded to D- from U on 05/17/2021.
OTC PK
03/10/2025 3:37PM Eastern
Quotes delayed
